Micregen Ltd , United Kingdom
None
Therapeutic Potential of MSC Secretomes Across Distinct Neurodegenerative Pathologies: Evidence from Alzheimer’s and Motor Neurone Disease Models
Robert obtained his PhD at the University of Reading, UK with his thesis specialising on the regenerative capabilities of the adult stem cell secretome, with a particular emphasis on its effect on skeletal muscle. Robert is a co-founder of Micregen and currently Director of R&D. Since 2019 Robert has managed and coordinated Micregen’s clinical manufacturing programme, preparing Micregen’s first therapeutic to enter a combined phase I/II clinical trial in the UK.
